<i>In vitro</i>activity of voriconazole against Mexican oral yeast isolates

Vargas, Luis Alberto; Eraso, Elena; Carrillo-Muñoz, Alfonso Javier; Aguirre, J.M.; Gaitán-Cepeda, Luis Alberto; Quindós, Guillermo

doi:10.1111/j.1439-0507.2009.01702.x

Cited by 7 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Table4, Voriconazole (VCZ) was the most effective drug in vitro with GMMICs of 0.957 𝜇g/ml, for C. albicans,Omran et al (2018) in Iran previously showed that the GM-MIC90 for Voriconazole (VCZ ) were 0.25 𝜇g/ml for C. albicans less than our findings[36]. Several other studies also demonstrated that Voriconazole (VCZ) was strong antifungal agents against Candida spp [36,[54][55][56][57]…”

contrasting

confidence: 58%

“…In the current study, 5% of However, the geometric MIC90 was 0.957 𝜇g/mL which is the lowest MIC90 for all tested drugs; the good in vitro activities of Voriconazole (VCZ) in the current study have been previously reported against Candida spp. obtained from oral candidacies patients[54][55][56]. As shown in Table4, Voriconazole (VCZ) was the most effective drug in vitro with GMMICs of 0.957 𝜇g/ml, for C. albicans,Omran et al (2018) in Iran previously showed that the GM-MIC90 for Voriconazole (VCZ ) were 0.25 𝜇g/ml for C. albicans less than our findings[36].…”

contrasting

confidence: 53%

See 1 more Smart Citation

In Vitro Antifungal Susceptibility of Candida Albicans Isolated from Yemeni Patients with Denture Stomatitis

Al-Shamahy¹

2022

JDOMS

View full text Add to dashboard Cite

Background and aims: Candida-associated denture stomatitis (CADS) is a common fungal infection in people who wear dentures. The main objectives of this study were to identify the causative agents of CADS and in vitro antifungal susceptibility testing (AFST) for Candida albicans in Yemeni patients with denture stomatitis. Methods: A total of 88 Candida spp. obtained from patients with denture stomatitis. Candida spp were identified using standard microbiological methods. The in-vitro antifungal susceptibility of Candida albicans. to fluconazole (FCZ), itraconazole (ICZ), voriconazole (VCZ), and amphotericin B (AMB) was evaluated using the E test strips. Interpretive sensitivity criteria for antifungal breakpoints were adapted from the Clinical and Laboratory Standards Institute (CLSI). Results: Overall, C. albicans was the most commonly isolated species (𝑛 = 60; 68.2%), followed by C. glabrata (𝑛 = 9; 10.2%), C. tropicalis (𝑛 = 7; 8%), and C. parapsilosis (𝑛 = 3; 3.4%). Voriconazole had the lowest geometric mean minimum inhibitory concentration which was 0.0418 𝜇g/ml for MIC50, and 0.957 𝜇g/ml for MIC90; followed by amphotericin B (AMB) in which MIC50 was 0.518 𝜇g/ml and for MIC90 was 1.06 𝜇g/ml. Conclusion: Our study showed that Candida albicans was the most prevalent Candida species in Yemeni patients with CADS and was susceptible to both azoles and amphotericin B. In addition, voriconazole could be a suitable alternative to antifungal agents currently used in the treatment of CADS, as well as in the treatment of recurrent Candidasis.

show abstract

contrasting

confidence: 58%

contrasting

confidence: 53%

In Vitro Antifungal Susceptibility of Candida Albicans Isolated from Yemeni Patients with Denture Stomatitis

Al-Shamahy¹

2022

JDOMS

View full text Add to dashboard Cite

show abstract

“…Antifungal testing of oral yeast isolates are crucial for the selection of antifungal agents and the prediction of clinical response in patients with HIV/AIDS [20,26]. In this study, we tested the antifungal activities of four widely used drugs in Kunming on yeast isolates.…”

Section: Discussionmentioning

confidence: 99%

“…Previous study have shown that HAART decreased the incidence of all HIV-related opportunistic infections including fungal infection [16], but there are conflicting reports regarding the association between oral yeast colonization and HAART [6,7,17-19]. Monitoring the antifungal susceptibility of clinical isolates from patients with HIV/AIDS has crucial importance for better treatment of these patients [20]. …”

Section: Introductionmentioning

confidence: 99%

Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China

Chen

et al. 2013

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundOral Candida colonization and its relation with predisposing factors in HIV-infected patients have received wide concerns during recent decades. In this study, we investigated asymptomatic oral Candida carriage rate, species distribution and antifungal susceptibility of 604 HIV-infected patients and 851 healthy individuals in Kunming, Yunnan Province of China.MethodsMucosal swab sampling was taken from each subject and CHROMagar Candida agar medium and API 20C AUX system were used to identify yeast isolates. In vitro antifungal susceptibility was tested by the broth microdilution method according to the M27-A2 document of the Clinical and Laboratory Standard Institute (CLSI).ResultsThe oral yeast colonization rate in HIV-infected patients (49.5%) was higher than that of healthy subjects (20.7%). Candida albicans constituted the most frequent species, accounting for 82.2% of yeast isolates. The remaining species were composed of C. glabrata, C. parapsilosis, C. krusei, C. tropicalis, C. rugosa, C. norvegensis, Pichia ohmeri and Saccharomyces cerevisiae. In HIV-infected patients, asymptomatic oral yeast colonization was associated with low CD4 cell count (<200 cells/mm3) and lack of highly active antiretroviral therapy (HAART). Different Candida species isolated from our samples presented different susceptibility to voriconazole, fluconazole and itraconazole. Amphotericin B had the best inhibiting effect for all isolates.ConclusionOral yeast colonization in Han Chinese patients with HIV from Kunming had common and unique features and was associated with CD4 cell number and HARRT. Amphotericin B should be used with first priority in controlling Candida infection in Han Chinese patients from Kunming. Our results provide first hand information on monitoring oral yeasts colonization in HIV-infected patients from Kunming, China.

show abstract

In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis

et al. 2011

View full text Add to dashboard Cite

Denture stomatitis is often treated with antifungal agents but recurrences or new episodes are common, and certain episodes can be resistant. New triazoles, such as posaconazole and voriconazole, may represent useful alternatives for management. In vitro activities of amphotericin B, nystatin, miconazole, fluconazole, itraconazole, posaconazole and voriconazole against 150 oral Candida (101 C. albicans, 18 C. tropicalis, 12 C. glabrata, 11 C. guilliermondii, 4 C. parapsilosis, 2 Saccharomyces cerevisiae, 1 C. dubliniensis and 1 C. krusei) from 100 denture wearers were tested by the CLSI M27-A3 method. Resistant isolates were retested by Sensititre YeastOne and Etest. Most antifungal agents were very active. However, 4 C. glabrata (33.3%), 2 C. tropicalis (11.1%), 6 C. albicans (5.6%) and 1 C. krusei were resistant to itraconazole. Posaconazole was active against 143 yeast isolates (95.3%): 6 C. albicans (5.9%) and 1 C. tropicalis (5.6%) were resistant. Geometric mean MICs were 0.036 μg/ml for C. parapsilosis, 0.062 μg/ml for C. albicans, 0.085 μg/ml for C. tropicalis, 0.387 μg/ml for C. guilliermondii and 0.498 μg/ml for C. glabrata. Voriconazole was active against 148 isolates (98.7%) with geometric mean MICs ranging from 0.030 μg/ml for C. parapsilosis, 0.042 μg/ml for C. albicans, 0.048 μg/ml for C. tropicalis, 0.082 μg/ml for C. guilliermondii, to 0.137 μg/ml for C. glabrata. Only 2 C. albicans (2%) were resistant to voriconazole showing cross-resistance to other azoles. Posaconazole and voriconazole have excellent in vitro activities against all Candida isolates and could represent useful alternatives for recalcitrant or recurrent candidiasis.

show abstract

In vitroactivity of voriconazole against Mexican oral yeast isolates

Cited by 7 publications

References 13 publications

In Vitro Antifungal Susceptibility of Candida Albicans Isolated from Yemeni Patients with Denture Stomatitis

In Vitro Antifungal Susceptibility of Candida Albicans Isolated from Yemeni Patients with Denture Stomatitis

Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China

In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis

Contact Info

Product

Resources

About